Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | STAT3 | P40763 | 5/20 | 0.34 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | VDR | P11473 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10180215 | 0.90 | HRH3 (0.35) | PRMT5JAK2BRD4THRAVDR | |
| SCHEMBL10181312 | 0.89 | GPR119 (0.48) | GPR119 | |
| SCHEMBL10180513 | 0.87 | FASN (0.36) | GPR119STAT3PRMT5JAK2BRD4 | |
| SCHEMBL10180803 | 0.86 | STAT3 (0.36) | STAT3PRMT5THRAVDR | |
| SCHEMBL10179883 | 0.85 | DRD2 (0.36) | GPR119PRMT5 | |
| SCHEMBL10187805 | 0.84 | STAT3 (0.36) | STAT3PRMT5 | |
| SCHEMBL10181103 | 0.83 | PRMT5 (0.34) | STAT3PRMT5THRAVDRTHRB | |
| SCHEMBL10181034 | 0.83 | GPR119 (0.45) | GPR119 | |
| SCHEMBL10179385 | 0.83 | PRMT5 (0.36) | PRMT5JAK2BRD4THRAVDR | |
| SCHEMBL10180156 | 0.83 | STAT3 (0.35) | GPR119STAT3PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | GPR119 1/4885STAT3 1743/4885TRPC6 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.